Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Belite Bio, Inc - American Depositary Shares (NQ: BLTE )

17.15 +0.13 (+0.76%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 2, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 61,374
Open 17.98
Bid (Size) 16.25 (1)
Ask (Size) 18.00 (6)
Prev. Close 17.02
Today's Range 16.66 - 17.99
52wk Range 14.22 - 44.70
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
12 Health Care Stocks Moving In Wednesday's Intraday Session
 
Via Benzinga
Why Capri Holdings Shares Are Trading Lower By Around 11%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers Aridis Pharmaceuticals, Inc. (NASDAQ: ARDS) shares jumped 143% to $0.45 after the company announced it received agreement from the FDA on its proposed single confirmatory Phase 3 study of... 
Via Benzinga

Performance

YTD
-42.45%
-42.45%
1 Month
-39.82%
-39.82%
3 Month
-46.72%
-46.72%
6 Month
-48.53%
-48.53%
1 Year
+15.49%
+15.49%

More News

Read More
Why Shares of Belite Bio Are Slumping Wednesday
Via The Motley Fool
Nasdaq Down 100 Points; Advance Auto Parts Earnings Miss Views
Via Benzinga
Dow Tumbles Over 200 Points; Chicago PMI Drops In May
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Why LL Flooring Shares Are Trading Higher By 19%; Here Are 20 Stocks Moving Premarket
Via Benzinga
HP, Ambarella, Sportsmans Warehouse And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Via Benzinga
Belite Bio Announces Pricing of $30 Million Underwritten Public Offering of American Depositary Shares and Warrants
From Belite Bio, Inc
Via GlobeNewswire
Belite Bio Announces Proposed Underwritten Public Offering of American Depositary Shares and Warrants
From Belite Bio, Inc
Via GlobeNewswire
Belite Bio Reports First-Quarter 2023 Operational Highlights and Financial Results
From Belite Bio, Inc
Via GlobeNewswire
Belite Bio to Host Webcast on May 11, 2023 to Discuss First Quarter 2023 Financial Results
From Belite Bio, Inc
Via GlobeNewswire
Belite Bio to Host Key Opinion Leader Webinar Discussing Progression of Childhood-onset STGD1 and Relevance of the Tinlarebant 18-month Phase 2 Data
From Belite Bio, Inc
Via GlobeNewswire
Belite Bio Presented 18-Month Interim Data from a 24-Month Phase 2 Study of Tinlarebant in Adolescent Stargardt Disease at the 2023 ARVO Meeting
From Belite Bio, Inc
Via GlobeNewswire
Belite Bio to Host Key Opinion Leader Webinar on RBP4 Antagonist Tinlarebant in Late-Stage Development for Stargardt Disease 1
From Belite Bio, Inc
Via GlobeNewswire
Belite Bio Reports Full-Year 2022 Operational Highlights and Financial Results
From Belite Bio, Inc
Via GlobeNewswire
Belite Bio to Host Webcast on April 3, 2023 to Discuss 2022 Full Year Financial Results
From Belite Bio, Inc
Via GlobeNewswire
3 Breakout Growth Stocks to Buy for the Long Haul
Via The Motley Fool
2 Stocks Up 165% and 209% in 2022 That Could Keep Soaring in 2023
Via The Motley Fool
Imago BioSciences, GrafTech International And Some Other Big Stocks Moving Higher On Monday
Via Benzinga
Why Drive Shack Shares Jumped Over 23%; Here Are 76 Biggest Movers From Yesterday
Via Benzinga
Belite Bio Finalizes Phase 3 Clinical Trial Plans for Advanced Dry AMD Treatment with Tinlarebant (LBS-008)
From Belite Bio, Inc
Via GlobeNewswire
Belite Bio to Host Key Opinion Leader Webinar on October 27, 2022 to discuss LBS-008 Interim Data
From Belite Bio, Inc
Via GlobeNewswire
3 Soaring Biotech Stocks That Could Climb Much Higher
Via The Motley Fool
Why Immunic Shares Jumped By Around 57%; Here Are 73 Biggest Movers From Yesterday
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.